RedHill Biopharma: Gains as COVID-19 drug study passes second safety review
07/10/2020 15:37
** Israeli drugmaker's U.S. shares RDHL.O rise 2.3% to
$9.67 in morning trade
** Co says U.S. mid-stage study of its investigational drug,
opaganib, in patients with severe COVID-19 pneumonia has passed
second safety review urn:newsml:reuters.com:*:nGNE8zrdv9
** Review by independent Safety Monitoring Committee
unanimously recommends continuation of study without change -
RDHL
** Recommendation based on safety data from first 24
patients treated in the study for at least 7 days
** Global emergency use authorization applications are
planned, subject to positive clinical results - RedHill
** Stock up ~57% this year
(Reporting by Sanjana Shivdas in Bengaluru)
((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))